Sanofi Stock

Equities

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris 04:21:33 2024-06-07 am EDT 5-day change 1st Jan Change
90.78 EUR -0.25% Intraday chart for Sanofi +1.09% +1.09%
Sales 2024 * 46.38B 50.51B Sales 2025 * 49.89B 54.34B Capitalization 114B 124B
Net income 2024 * 7.08B 7.71B Net income 2025 * 8.69B 9.47B EV / Sales 2024 * 2.6 x
Net Debt 2024 * 6.92B 7.53B Net Debt 2025 * 2.29B 2.5B EV / Sales 2025 * 2.33 x
P/E ratio 2024 *
16.4 x
P/E ratio 2025 *
13.2 x
Employees 86,088
Yield 2024 *
4.25%
Yield 2025 *
4.47%
Free-Float 87.13%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.35%
1 week+2.75%
Current month+1.39%
1 month-0.01%
3 months+4.47%
6 months+5.67%
Current year+1.39%
More quotes
1 week
88.00
Extreme 88
91.51
1 month
87.04
Extreme 87.04
94.47
Current year
84.93
Extreme 84.93
96.50
1 year
80.60
Extreme 80.6
104.32
3 years
76.45
Extreme 76.45
106.66
5 years
67.65
Extreme 67.65
106.66
10 years
62.50
Extreme 62.5
106.66
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 19-08-31
Chief Operating Officer 40 21-12-31
Chief Tech/Sci/R&D Officer 51 -
Members of the board TitleAgeSince
Director/Board Member 70 14-04-30
Director/Board Member 62 20-04-27
Director/Board Member 64 20-05-21
More insiders
Date Price Change Volume
24-06-07 90.78 -0.25% 74 184
24-06-06 91.01 +0.35% 1,077,180
24-06-05 90.69 +0.47% 1,125,198
24-06-04 90.27 +0.18% 1,471,885
24-06-03 90.11 +0.39% 1,449,066

Real-time Euronext Paris, June 06, 2024 at 11:39 am EDT

More quotes
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
91.01 EUR
Average target price
108.2 EUR
Spread / Average Target
+18.88%
Consensus